Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
Paying homage to Parkway Drive's Ben Gordon, Polaris's Dan Furnari, Stray From The Path's Craig Reynolds & more The post RedHook’s Alex Powys Talks 10 Drummers Who Influenced His Playing On ‘Mutation’ ...
Kurnool: Joint Collector Noorul Qamar has directed the revenue machinery to complete the ongoing re-survey process in the ...
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid ...
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...
Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more ...
Morning Overview on MSN
A tiny mutation can derail brain growth for life, study finds
A single microscopic change in our DNA can permanently alter how the brain is built, locking in developmental problems that ...
The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive ...
SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback